Peroxisome Proliferator-Activated Receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity.

Medical Department M, Aarhus University Hospital, Aarhus Sygehus, DK-8000 Aarhus C, Denmark.

Context: Peroxisome Proliferator-Activated Receptor gamma (PPARgamma) agonists such as thiazolidinediones (TZD) improve insulin sensitivity in type 2 diabetes via effects on fat metabolism, whereas growth hormone (GH) stimulates lipolysis and induces insulin resistance. Objective: To evaluate the impact of TZD on fat metabolism and insulin sensitivity in subjects exposed to stable GH levels. Design: Randomized, placebo-controlled, double-blind parallel-group study including 20 GH-deficient patients on continued GH replacement therapy. The patients were studied before and after 12 weeks. Intervention: Patients received either pioglitazone 30 mg (N = 10) or placebo (N = 10) once daily for 12 weeks. Results: Adiponectin levels almost doubled during pioglitazone treatment (P = 0.0001). Pioglitazone significantly decreased basal free fatty acid levels (P = 0.02) and lipid oxidation (P = 0.02). Basal glucose oxidation rate (P = 0.004) and insulin sensitivity (P = 0.03) improved in the patients who received pioglitazone treatment. The change in insulin-stimulated adiponectin level after pioglitazone treatment was positively correlated to the change in insulin-stimulated total glucose disposal (R = 0.69, P = 0.04). Conclusion: The impact of GH on lipolysis and insulin sensitivity is modifiable by administration of TZD.

PMID: 18331610 [PubMed - as supplied by publisher]